CN100363375C - 红霉素衍生物 - Google Patents

红霉素衍生物 Download PDF

Info

Publication number: CN100363375C
Authority: CN; China
Prior art keywords: methyl; product; dideoxy; acid; formula
Prior art date: 1996-12-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CNB2005100874942A

Other languages

English (en)

Chinese (zh)

Other versions

CN1721427A (zh

Inventor

J·-M·奥格尔

C·阿古里达斯

J·-F·尚托特

A·德尼

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Aventis Pharma SA

Original Assignee

Aventis Pharma SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-12-12

Filing date

1997-12-10

Publication date

2008-01-23

1997-12-10 Application filed by Aventis Pharma SA filed Critical Aventis Pharma SA

2006-01-18 Publication of CN1721427A publication Critical patent/CN1721427A/zh

2008-01-23 Application granted granted Critical

2008-01-23 Publication of CN100363375C publication Critical patent/CN100363375C/zh

2017-12-10 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical class O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 title description 15
150000001875 compounds Chemical class 0.000 claims abstract description 14
125000004432 carbon atom Chemical group C* 0.000 claims description 10
150000002084 enol ethers Chemical class 0.000 claims description 4
150000001261 hydroxy acids Chemical group 0.000 claims 1
239000000126 substance Substances 0.000 claims 1
125000003118 aryl group Chemical group 0.000 abstract description 7
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract description 5
230000003115 biocidal effect Effects 0.000 abstract description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 abstract description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
239000000047 product Substances 0.000 description 27
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 12
229910052760 oxygen Inorganic materials 0.000 description 12
239000001301 oxygen Substances 0.000 description 12
239000003814 drug Substances 0.000 description 11
239000000243 solution Substances 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000001035 drying Methods 0.000 description 8
238000002360 preparation method Methods 0.000 description 7
-1 pyrryl Chemical group 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
239000002253 acid Substances 0.000 description 6
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 6
229960003276 erythromycin Drugs 0.000 description 6
238000003810 ethyl acetate extraction Methods 0.000 description 6
239000000203 mixture Substances 0.000 description 6
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 5
239000000908 ammonium hydroxide Substances 0.000 description 5
125000005843 halogen group Chemical group 0.000 description 5
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 5
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
239000011541 reaction mixture Substances 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
238000003756 stirring Methods 0.000 description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
125000001072 heteroaryl group Chemical group 0.000 description 4
125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
150000002576 ketones Chemical class 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
238000000034 method Methods 0.000 description 4
206010041925 Staphylococcal infections Diseases 0.000 description 3
241000191940 Staphylococcus Species 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
239000000460 chlorine Substances 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
125000000623 heterocyclic group Chemical group 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000005406 washing Methods 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
241000193985 Streptococcus agalactiae Species 0.000 description 2
241001134658 Streptococcus mitis Species 0.000 description 2
241000193998 Streptococcus pneumoniae Species 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
125000003342 alkenyl group Chemical group 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
229910052801 chlorine Inorganic materials 0.000 description 2
239000012895 dilution Substances 0.000 description 2
238000010790 dilution Methods 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
230000000694 effects Effects 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
TYZYRCHEVXXLSJ-UHFFFAOYSA-N phenylmethoxymethoxymethoxymethylbenzene Chemical compound C=1C=CC=CC=1COCOCOCC1=CC=CC=C1 TYZYRCHEVXXLSJ-UHFFFAOYSA-N 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
229940031000 streptococcus pneumoniae Drugs 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
235000012222 talc Nutrition 0.000 description 2
LDMOEFOXLIZJOW-UHFFFAOYSA-N 1-dodecanesulfonic acid Chemical compound CCCCCCCCCCCCS(O)(=O)=O LDMOEFOXLIZJOW-UHFFFAOYSA-N 0.000 description 1
BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
125000005975 2-phenylethyloxy group Chemical group 0.000 description 1
YFOKBFRTGLSZLU-UHFFFAOYSA-N 3-(1h-imidazol-5-yl)pyridine Chemical class N1C=NC=C1C1=CC=CN=C1 YFOKBFRTGLSZLU-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
206010006500 Brucellosis Diseases 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010013786 Dry skin Diseases 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
241000194031 Enterococcus faecium Species 0.000 description 1
201000000297 Erysipelas Diseases 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
206010017553 Furuncle Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
208000005141 Otitis Diseases 0.000 description 1
208000035109 Pneumococcal Infections Diseases 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
206010039587 Scarlet Fever Diseases 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
206010056430 Staphylococcal sepsis Diseases 0.000 description 1
241000191963 Staphylococcus epidermidis Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010061372 Streptococcal infection Diseases 0.000 description 1
241000193996 Streptococcus pyogenes Species 0.000 description 1
241000223996 Toxoplasma Species 0.000 description 1
241000202898 Ureaplasma Species 0.000 description 1
MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
206010000496 acne Diseases 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
125000000304 alkynyl group Chemical group 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000003851 azoles Chemical class 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
HRQGCQVOJVTVLU-UHFFFAOYSA-N bis(chloromethyl) ether Chemical compound ClCOCCl HRQGCQVOJVTVLU-UHFFFAOYSA-N 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
125000001309 chloro group Chemical group Cl* 0.000 description 1
238000013375 chromatographic separation Methods 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
238000007865 diluting Methods 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
208000019258 ear infection Diseases 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
125000004970 halomethyl group Chemical group 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000002674 ointment Substances 0.000 description 1
150000007524 organic acids Chemical group 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000000505 pernicious effect Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000005493 quinolyl group Chemical group 0.000 description 1
239000002994 raw material Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000010898 silica gel chromatography Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
235000017550 sodium carbonate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Communicable Diseases (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicinal Preparation (AREA)

CNB2005100874942A 1996-12-12 1997-12-10 红霉素衍生物 Expired - Lifetime CN100363375C (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
FR9615271A FR2757168B1 (fr)	1996-12-12	1996-12-12	Nouveaux derives de l'erythromycine, leur procede de preparation et leur application comme medicaments
FR96/15271		1996-12-12

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CNB971804966A Division CN1238364C (zh)	1996-12-12	1997-12-10	红霉素衍生物,其制备方法及其作为药物的用途

Publications (2)

Publication Number	Publication Date
CN1721427A CN1721427A (zh)	2006-01-18
CN100363375C true CN100363375C (zh)	2008-01-23

Family

ID=9498593

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
CNB2005100874942A Expired - Lifetime CN100363375C (zh)	1996-12-12	1997-12-10	红霉素衍生物
CNB971804966A Expired - Lifetime CN1238364C (zh)	1996-12-12	1997-12-10	红霉素衍生物,其制备方法及其作为药物的用途

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CNB971804966A Expired - Lifetime CN1238364C (zh)	1996-12-12	1997-12-10	红霉素衍生物,其制备方法及其作为药物的用途

Country Status (28)

Country	Link
EP (1)	EP0946579B1 (fr)
JP (1)	JP4363666B2 (fr)
KR (1)	KR100490074B1 (fr)
CN (2)	CN100363375C (fr)
AP (1)	AP997A (fr)
AT (1)	ATE217008T1 (fr)
AU (1)	AU721732B2 (fr)
BG (1)	BG63124B1 (fr)
BR (1)	BR9714007A (fr)
CA (1)	CA2273985C (fr)
CZ (1)	CZ292403B6 (fr)
DE (1)	DE69712361T2 (fr)
DK (1)	DK0946579T3 (fr)
EA (1)	EA001733B1 (fr)
ES (1)	ES2174323T3 (fr)
FR (1)	FR2757168B1 (fr)
GE (1)	GEP20012518B (fr)
HU (1)	HUP0001180A3 (fr)
ID (1)	ID21873A (fr)
IL (1)	IL130420A (fr)
NO (1)	NO314040B1 (fr)
NZ (1)	NZ335325A (fr)
PT (1)	PT946579E (fr)
SK (1)	SK283715B6 (fr)
TR (1)	TR199901301T2 (fr)
WO (1)	WO1998025942A1 (fr)
YU (1)	YU25699A (fr)
ZA (1)	ZA9711101B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2771008B1 (fr) *	1997-11-17	2000-04-28	Hoechst Marion Roussel Inc	Utilisation des ketolides pour la preparation de compositions pharmaceutiques destinees a prevenir les complications thrombotiques arterielles liees a l'atherosclerose
DE69933897T2 (de) *	1998-12-10	2007-03-15	Pfizer Products Inc., Groton	Carbamat- und Carbazatketolid-Antibiotika
CA2359708C (fr)	1999-01-27	2005-10-25	Pfizer Products Inc.	Antibiotiques cetolides
ATE340183T1 (de) *	1999-04-16	2006-10-15	Kosan Biosciences Inc	Antiinfektiöse makrolidderivate
HUP0201516A3 (en)	1999-05-24	2003-03-28	Pfizer Prod Inc	13-methyl-erythromycin derivatives, process for their preparation and pharmaceutical compositions containing them
US6472372B1 (en) *	2000-12-06	2002-10-29	Ortho-Mcneil Pharmaceuticals, Inc.	6-O-Carbamoyl ketolide antibacterials
DK200201957A (da) *	2002-12-20	2003-01-20	Alpharma Aps	10-substituted erythromycin ketolides and methods of making

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0248279A2 (fr) *	1986-06-04	1987-12-09	Abbott Laboratories	Erythromycine semisynthétique à activité antibiotique
EP0487411A1 (fr) *	1990-11-21	1992-05-27	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, les nouveaux intermédiaires obtenus et leur application comme médicaments
EP0596802A1 (fr) *	1992-11-05	1994-05-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, leur application comme médicaments
EP0676409A1 (fr) *	1994-04-08	1995-10-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE135707T1 (de) *	1992-04-22	1996-04-15	Taisho Pharmaceutical Co Ltd	5-0-desosaminylerythronolid a derivate
JP3709997B2 (ja) *	1994-03-29	2005-10-26	日東電工株式会社	耐熱性ネガ型フォトレジスト組成物および感光性基材、ならびにネガ型パターン形成方法
FR2719587B1 (fr) *	1994-05-03	1996-07-12	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.

1996
- 1996-12-12 FR FR9615271A patent/FR2757168B1/fr not_active Expired - Fee Related
1997
- 1997-12-01 AP APAP/P/1999/001513A patent/AP997A/en active
- 1997-12-10 IL IL13042097A patent/IL130420A/xx not_active IP Right Cessation
- 1997-12-10 AU AU54877/98A patent/AU721732B2/en not_active Ceased
- 1997-12-10 YU YU25699A patent/YU25699A/sh unknown
- 1997-12-10 DE DE69712361T patent/DE69712361T2/de not_active Expired - Lifetime
- 1997-12-10 ES ES97951293T patent/ES2174323T3/es not_active Expired - Lifetime
- 1997-12-10 EP EP97951293A patent/EP0946579B1/fr not_active Expired - Lifetime
- 1997-12-10 CA CA002273985A patent/CA2273985C/fr not_active Expired - Lifetime
- 1997-12-10 NZ NZ335325A patent/NZ335325A/xx unknown
- 1997-12-10 ZA ZA9711101A patent/ZA9711101B/xx unknown
- 1997-12-10 KR KR10-1999-7005216A patent/KR100490074B1/ko not_active Expired - Lifetime
- 1997-12-10 ID IDW990504A patent/ID21873A/id unknown
- 1997-12-10 PT PT97951293T patent/PT946579E/pt unknown
- 1997-12-10 BR BR9714007-4A patent/BR9714007A/pt active Search and Examination
- 1997-12-10 JP JP52629898A patent/JP4363666B2/ja not_active Expired - Lifetime
- 1997-12-10 AT AT97951293T patent/ATE217008T1/de not_active IP Right Cessation
- 1997-12-10 GE GEAP19974895A patent/GEP20012518B/en unknown
- 1997-12-10 CZ CZ19992082A patent/CZ292403B6/cs not_active IP Right Cessation
- 1997-12-10 SK SK750-99A patent/SK283715B6/sk unknown
- 1997-12-10 WO PCT/FR1997/002254 patent/WO1998025942A1/fr not_active Ceased
- 1997-12-10 CN CNB2005100874942A patent/CN100363375C/zh not_active Expired - Lifetime
- 1997-12-10 EA EA199900528A patent/EA001733B1/ru not_active IP Right Cessation
- 1997-12-10 TR TR1999/01301T patent/TR199901301T2/xx unknown
- 1997-12-10 CN CNB971804966A patent/CN1238364C/zh not_active Expired - Lifetime
- 1997-12-10 HU HU0001180A patent/HUP0001180A3/hu unknown
- 1997-12-10 DK DK97951293T patent/DK0946579T3/da active
1999
- 1999-05-12 BG BG103398A patent/BG63124B1/bg unknown
- 1999-06-11 NO NO19992859A patent/NO314040B1/no not_active IP Right Cessation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0248279A2 (fr) *	1986-06-04	1987-12-09	Abbott Laboratories	Erythromycine semisynthétique à activité antibiotique
EP0487411A1 (fr) *	1990-11-21	1992-05-27	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, les nouveaux intermédiaires obtenus et leur application comme médicaments
EP0596802A1 (fr) *	1992-11-05	1994-05-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation, leur application comme médicaments
EP0676409A1 (fr) *	1994-04-08	1995-10-11	Roussel Uclaf	Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments

Also Published As

Publication number	Publication date
JP4363666B2 (ja)	2009-11-11
NO992859L (no)	1999-06-11
TR199901301T2 (xx)	1999-08-23
AP997A (en)	2001-08-09
GEP20012518B (en)	2001-08-27
EA001733B1 (ru)	2001-08-27
EP0946579A1 (fr)	1999-10-06
DK0946579T3 (da)	2002-08-12
CZ292403B6 (cs)	2003-09-17
SK283715B6 (sk)	2003-12-02
NO992859D0 (no)	1999-06-11
BG63124B1 (bg)	2001-04-30
HUP0001180A3 (en)	2003-05-28
NZ335325A (en)	2000-08-25
IL130420A0 (en)	2000-06-01
JP2001506620A (ja)	2001-05-22
SK75099A3 (en)	2000-01-18
ID21873A (id)	1999-08-05
ATE217008T1 (de)	2002-05-15
CZ208299A3 (cs)	1999-09-15
KR20000057517A (ko)	2000-09-15
AU721732B2 (en)	2000-07-13
DE69712361T2 (de)	2002-11-28
CA2273985C (fr)	2007-03-20
AP9901513A0 (en)	1999-06-30
YU25699A (sh)	2002-06-19
AU5487798A (en)	1998-07-03
PT946579E (pt)	2002-10-31
FR2757168A1 (fr)	1998-06-19
FR2757168B1 (fr)	1999-06-11
EA199900528A1 (ru)	1999-12-29
NO314040B1 (no)	2003-01-20
CN1239966A (zh)	1999-12-29
HUP0001180A2 (hu)	2000-09-28
WO1998025942A1 (fr)	1998-06-18
EP0946579B1 (fr)	2002-05-02
ZA9711101B (en)	1998-12-10
IL130420A (en)	2003-01-12
BG103398A (en)	2000-01-31
BR9714007A (pt)	2000-05-09
CN1238364C (zh)	2006-01-25
KR100490074B1 (ko)	2005-05-17
CN1721427A (zh)	2006-01-18
CA2273985A1 (fr)	1998-06-18
ES2174323T3 (es)	2002-11-01
DE69712361D1 (de)	2002-06-06

Legal Events

Date	Code	Title	Description
2006-01-18	C06	Publication
2006-01-18	PB01	Publication
2006-03-08	C10	Entry into substantive examination
2006-03-08	SE01	Entry into force of request for substantive examination
2008-01-23	C14	Grant of patent or utility model
2008-01-23	GR01	Patent grant
2018-01-23	CX01	Expiry of patent term
2018-01-23	CX01	Expiry of patent term	Granted publication date: 20080123

Publication	Publication Date	Title
JP4102440B2 (ja)	2008-06-18	新規なエリスロマイシン誘導体、それらの調製方法及びそれらの医薬品としての使用
KR20000057017A (ko)	2000-09-15	에리트로마이신의 신규한 유도체, 그의 제조 방법 및약제로서의 그의 용도
CN100363375C (zh)	2008-01-23	红霉素衍生物
KR100285972B1 (ko)	2001-05-02	에리트로마이신 유도체, 그의 제조 방법 및 의약으로서의 용도
KR100458240B1 (ko)	2004-11-26	신규 에리트로마이신 유도체, 그의 제조방법 및 의약으로서의용도
JP5188520B2 (ja)	2013-04-24	新規なエリスロマイシン誘導体、製造方法及び医薬としての利用
EP1846430B1 (fr)	2009-04-01	Nouveaux macrolides
EP1181298B1 (fr)	2006-07-19	Nouveaux lactames 8a et 9a a 15 elements
US5780604A (en)	1998-07-14	11,12-cyclic phosphite or phosphate derivatives of erythromycin and related macrolides
JP4583601B2 (ja)	2010-11-17	新規の６−デオキシエリスロマイシン誘導体、それらの製造方法及びそれらの薬剤としての使用
MXPA99005226A (en)	2000-01-01	Novel erythromycin derivatives, method for preparing them and their use as medicine